CANF Stock Overview
A clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Can-Fite BioPharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.033 |
| 52 Week High | ₪0.041 |
| 52 Week Low | ₪0.025 |
| Beta | 0.65 |
| 11 Month Change | 22.22% |
| 3 Month Change | 13.79% |
| 1 Year Change | -15.38% |
| 33 Year Change | -86.64% |
| 5 Year Change | -90.73% |
| Change since IPO | -99.90% |
Recent News & Updates
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year
Jun 19
Recent updates
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year
Jun 19Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?
Jun 30We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate
Mar 08Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?
Nov 21Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely
May 16We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate
Jan 31
Shareholder Returns
| CANF | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -8.3% | 1.0% | 0.9% |
| 1Y | -15.4% | -16.9% | -3.2% |
Return vs Industry: CANF exceeded the IL Biotechs industry which returned -16.9% over the past year.
Return vs Market: CANF underperformed the IL Market which returned -3.2% over the past year.
Price Volatility
| CANF volatility | |
|---|---|
| CANF Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 7.8% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: CANF has not had significant price volatility in the past 3 months.
Volatility Over Time: CANF's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 8 | Motti Farbstein | www.canfite.com |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
Can-Fite BioPharma Ltd. Fundamentals Summary
| CANF fundamental statistics | |
|---|---|
| Market cap | ₪50.90m |
| Earnings (TTM) | -₪28.74m |
| Revenue (TTM) | ₪2.80m |
17.7x
P/S Ratio-1.7x
P/E RatioIs CANF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANF income statement (TTM) | |
|---|---|
| Revenue | US$743.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$743.00k |
| Other Expenses | US$8.38m |
| Earnings | -US$7.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0051 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,027.46% |
| Debt/Equity Ratio | 0% |
How did CANF perform over the long term?
See historical performance and comparison